Global News

Janssen, Bayer, Portola form clinical collaboration

Friday, February 8, 2013 11:17 AM

Janssen Pharmaceuticals has signed a clinical collaboration agreement with Portola Pharmaceuticals and Bayer HealthCare to evaluate the safety of PRT4445—an investigational-stage antidote for Factor Xa inhibitors—in healthy volunteers who have been administered the oral anticoagulant Xarelto (rivaroxaban). The study will evaluate several dosage strengths of PRT4445 and its ability to reverse the anticoagulant activity of Xarelto in emergency situations.

More... »

Oracle unveils new version of ClearTrial Plan and Source Enterprise

Wednesday, February 6, 2013 01:21 PM

Oracle Health Sciences has released Oracle Health Sciences ClearTrial Plan and Source Enterprise Edition Cloud Service 5.0, the latest version of the cloud-based clinical trial operations solution that enables life sciences organizations to plan, source and track clinical projects and financial performance via a single, integrated platform.

More... »

Exco InTouch joins C-Path ePRO Consortium

Wednesday, February 6, 2013 12:10 PM

Exco InTouch, a provider of patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, a program run by nonprofit Critical Path Institute (C-Path), which strives to enhance the quality of patient reported outcomes (PRO) in the evaluation of new pharmaceuticals. 

More... »

Biogen Idec acquires full rights of Tysabri from Elan

Wednesday, February 6, 2013 11:41 AM

Biogen Idec, an independent biotechnology company, has agreed to purchase biotech Elan’s full strategic, commercial and decision-making rights to Tysabri.

More... »

Gilead Sciences acquires YM BioSciences

Wednesday, February 6, 2013 11:12 AM

The Supreme Court of Nova Scotia has issued a final order approving the previously announced plan involving YM BioSciences, Gilead Sciences and Nova Scotia Limited, a wholly-owned subsidiary of Gilead. Nova Scotia Limited will acquire all of the issued and outstanding common shares of YM BioSciences for cash consideration of $2.95 per common share.

More... »

GSK supports AllTrials campaign for clinical data transparency

Wednesday, February 6, 2013 10:14 AM

GlaxoSmithKline (GSK) has further demonstrated its commitment to clinical trial transparency by announcing its support for the AllTrials campaign. The campaign is calling for registration of clinical trials and the disclosure of clinical trial results and clinical study reports (CSRs) to help drive further scientific understanding.

More... »

MicroConstants China to provide site management services to Chinese hospital

Monday, February 4, 2013 03:39 PM

CRO MicroConstants China, which conducts preclinical pharmacokinetic studies, early-stage clinical trials and regulated bioanalysis in China, has signed a strategic collaboration agreement with the clinical research center of the No. 307 Hospital of People's Liberation Army to provide site management services.

More... »

GVK Biosciences, Endo collaborate on novel small molecules

Monday, February 4, 2013 03:12 PM

India-based CRO GVK Biosciences has entered into a collaboration agreement with U.S.-based Endo Pharmaceuticals, focusing on discovering novel small molecules targeting an exciting protein.

More... »

CRF Health first to achieve Gold Standard of Juniper’s ACQ, AQLQ ePRO instruments on the TrialMax Platform

Monday, February 4, 2013 02:43 PM

CRF Health, the developer of the TrialMax Suite of electronic Clinical Outcome Assessment Solutions (eCOA) for the life sciences industry, became the first eCOA company to complete a full validation study for professor Elizabeth F. Juniper’s ACQ and AQLQ questionnaires to the “Gold Standard” based on her recently released “Levels of Acceptability of Electronic Versions” rating system.

More... »

Medical societies to launch large-scale study on vein filter use

Monday, February 4, 2013 11:56 AM

The Society of Interventional Radiology (SIR) and Society for Vascular Surgery (SVS) jointly will launch PRESERVE—the first large-scale, multi-specialty prospective study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment.

More... »